EARLY ANTIBIOTIC THERAPY, INTESTINAL DYSBIOSIS AND IMMUNOLOGICAL CHANGES IN NEWBORNS

This article discusses the effects of early antibiotic therapy on intestinal microbiota, the mechanisms of dysbiosis development, and immunological changes in newborns. In the neonatal period, inappropriate or prolonged use of antibiotics may lead to a reduction in beneficial intestinal microorganisms, increased susceptibility to pathogenic flora, and impairment of immune responses. Disruption of intestinal microbiota can increase the risk of allergic diseases, metabolic disorders, necrotizing enterocolitis, and infectious diseases in infants. The article also provides information on the rational use of antibiotic therapy, the importance of probiotics, and preventive measures based on modern scientific data. The neonatal period is one of the most critical stages of human development, during which the intestinal microbiota and immune system undergo active formation. Early antibiotic therapy is widely used in neonatal medicine for the prevention and treatment of severe bacterial infections. However, irrational or prolonged antibiotic use may negatively affect the developing intestinal microflora, leading to intestinal dysbiosis and immunological disturbances. This article discusses the impact of early antibiotic therapy on neonatal intestinal microbiota, the mechanisms of dysbiosis development, associated immune changes, and possible long-term health consequences. Modern preventive approaches, including rational antibiotic use, breastfeeding, and probiotic support, are also highlighted.